UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000051835
Receipt number R000059153
Scientific Title Efficacy of antipsychotics alone in preventing delirium in cancer patients.: a systematic review
Date of disclosure of the study information 2023/08/05
Last modified on 2024/02/05 10:02:07

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy of antipsychotics alone in preventing delirium in cancer patients.: a systematic review

Acronym

Efficacy of antipsychotics alone in preventing delirium in cancer patients.: a systematic review

Scientific Title

Efficacy of antipsychotics alone in preventing delirium in cancer patients.: a systematic review

Scientific Title:Acronym

Efficacy of antipsychotics alone in preventing delirium in cancer patients.: a systematic review

Region

Japan


Condition

Condition

Cancer

Classification by specialty

Hematology and clinical oncology Psychiatry

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To verify the efficacy of antipsychotics alone in preventing delirium in cancer patients

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Delirium incidence

Key secondary outcomes

Delirium severity, deaths, tumbling and falls, extrapyramidal symptoms


Base

Study type

Others,meta-analysis etc


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1.Patients with cancer (more than or equal to 80%)
2.Patients without delirium before intervention
3.Studies examining the efficacy of antipsychotic medication alone for the prevention of delirium in adult cancer patients

The study design to be considered for inclusion is as follows:
1.If there were at least two randomized controlled trial (RCT)s, inclusion was completed.
2.If there were less than 2 RCTs, we included non-RCTs or observational studies with control groups.
3.If there were no RCTs/non-RCTs/observational studies with control groups, single-arm observational studies were considered for inclusion.

Key exclusion criteria

1.Duplicated publications
2.Conference proceedings
3.Reviews which are not based on systematic review
4.Study protocols
5.Case reports and case series
6.Articles written in languages other than English or Japanese

Target sample size



Research contact person

Name of lead principal investigator

1st name TETSURO
Middle name
Last name ISHIDA

Organization

Japan Healthcare University

Division name

Department of Psychiatry

Zip code

062-0053

Address

Higashi 3-11-1-55 Toyohira-ku Tsukisamu, Sapporo, Hokkaido Japan

TEL

011-852-6777

Email

teturoisida@yahoo.co.jp


Public contact

Name of contact person

1st name TETSURO
Middle name
Last name ISHIDA

Organization

Japan Healthcare University

Division name

Department of Psychiatry

Zip code

062-0053

Address

Higashi 3-11-1-55 Toyohira-ku Tsukisamu, Sapporo, Hokkaido Japan

TEL

011-852-6777

Homepage URL


Email

teturoisida@yahoo.co.jp


Sponsor or person

Institute

Japan Healthcare University

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

N/A

Address

N/A

Tel

N/A

Email

N/A


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 08 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2023 Year 07 Month 31 Day

Date of IRB

2023 Year 07 Month 31 Day

Anticipated trial start date

2023 Year 09 Month 01 Day

Last follow-up date

2024 Year 08 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Data sources and search strategy.
We will conduct a systematic review of randomized clinical trials to verify the effectiveness of Ramelteon for preventing delirium in cancer patients. This systematic review will search the following four databases: the Ichushi-Web of the Japan Medical Abstracts Society ver.5, Cochrane Library, EMBASE and MEDLINE, on 0831 2023. The search will include all relevant terms such as "Delirium, tumour or cancer, prevention or primary prevention or avoidance or reduction,"and "antipsychotic or quetiapine or risperidone or olanzapine or haloperidol or perospirone or chlorpromazine or aripiprazole or brexpiprazole or blonanserin or asenapine or lurasidone."

Selection of studies and Assessment of risk of bias in included studies.
Two review authors will independently check to ensure that studies meet the inclusion criteria. Two review authors will independently assess trial quality according to the Minds 2020 manual. If the raters disagree, the final rating will be made by consensus with the involvement, if necessary, of another review author.


Management information

Registered date

2023 Year 08 Month 05 Day

Last modified on

2024 Year 02 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000059153


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name